- Home
- OPP vs OCGN Comparison
OPP vs OCGN Comparison
Compare OPP & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- OCGN
- Stock Information
- Founded
- OPP 2010
- OCGN 2013
- Country
- OPP United States
- OCGN United States
- Employees
- OPP N/A
- OCGN N/A
- Industry
- OPP Finance/Investors Services
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPP Finance
- OCGN Health Care
- Exchange
- OPP Nasdaq
- OCGN Nasdaq
- Market Cap
- OPP 204.1M
- OCGN 229.2M
- IPO Year
- OPP N/A
- OCGN N/A
- Fundamental
- Price
- OPP $8.54
- OCGN $0.68
- Analyst Decision
- OPP
- OCGN Strong Buy
- Analyst Count
- OPP 0
- OCGN 3
- Target Price
- OPP N/A
- OCGN $6.00
- AVG Volume (30 Days)
- OPP 108.0K
- OCGN 3.5M
- Earning Date
- OPP 01-01-0001
- OCGN 03-05-2025
- Dividend Yield
- OPP 14.41%
- OCGN N/A
- EPS Growth
- OPP N/A
- OCGN N/A
- EPS
- OPP N/A
- OCGN N/A
- Revenue
- OPP N/A
- OCGN $4,700,000.00
- Revenue This Year
- OPP N/A
- OCGN N/A
- Revenue Next Year
- OPP N/A
- OCGN N/A
- P/E Ratio
- OPP N/A
- OCGN N/A
- Revenue Growth
- OPP N/A
- OCGN N/A
- 52 Week Low
- OPP $7.26
- OCGN $0.64
- 52 Week High
- OPP $8.83
- OCGN $2.11
- Technical
- Relative Strength Index (RSI)
- OPP 50.73
- OCGN 40.75
- Support Level
- OPP $8.53
- OCGN $0.67
- Resistance Level
- OPP $8.77
- OCGN $0.76
- Average True Range (ATR)
- OPP 0.07
- OCGN 0.04
- MACD
- OPP -0.01
- OCGN 0.00
- Stochastic Oscillator
- OPP 17.86
- OCGN 28.57
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").